A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01886469 |
|
Recruitment Status :
Completed
First Posted : June 26, 2013
Last Update Posted : October 3, 2014
|
Sponsor:
Ironshore Pharmaceuticals and Development, Inc
Information provided by (Responsible Party):
Ironshore Pharmaceuticals and Development, Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | September 2013 |
| Actual Study Completion Date : | September 2013 |